Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Lung cancer is responsible for highest mortality rates among both men and women globally. There is a need of effective and safe treatment modality that specifically targets cancer cells and doesn't not harm healthy cells. Procyanidolic oligomers (PCOs) is a natural antioxidant found in grape seed, acts as medicament for the treatment of various disease which are linked with oxidative stress specifically cancer. The aim of the current study was to synthesize highly stable gliadin encapsulated PCOs nanoformulation (PCO-NF). The PCOs nanoformulation (PCO-NF) showed spherical morphology (17.18-76.56 nm) with an average particle size 49.37 ± 22.17 nm diameter in electron microscopy and stable zeta potential i.e. - 23.1 mV and low polydispersity index i.e. 0.246 in dynamic light scattering (DLS). The therapeutic efficacy of PCO-NF has been evaluated through antioxidative, anticancer as well as antimicrobial studies. Antioxidant potency was assessed using DPPH scavenging assay and it was observed that IC of PCO-NF (9.02 µg/ml) was even lower than that of Vitamin C (10.22 µg/ml) as well as pure PCOs. The MTT assay was performed for the comparative anticancer activity of pure PCOs and PCO-NF against SK-MES-1 lung cancer cell line. It was found that PCO-NF significantly inhibited the lung cancer cells at all tested concentration. Moreover at 125 µg/ml concentration the PCO-NF showed 31.54% cell viability which was even lesser than the standard anticancer drug. The antimicrobial efficacy of PCO-NF was assessed against gram-positive and gram-negative bacteria. An augmented antimicrobial, antioxidant and anticancer potential was observed due to nanoencapsulation of PCOs.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12069783PMC
http://dx.doi.org/10.1007/s12088-024-01380-wDOI Listing

Publication Analysis

Top Keywords

lung cancer
12
gliadin encapsulated
8
procyanidolic oligomers
8
antimicrobial antioxidant
8
anticancer potential
8
cancer cells
8
pcos nanoformulation
8
pco-nf
8
nanoformulation pco-nf
8
efficacy pco-nf
8

Similar Publications

Purpose: mutations are classically seen in non-small cell lung cancers (NSCLCs), and EGFR-directed inhibitors have changed the therapeutic landscape in patients with -mutated NSCLC. The real-world prevalence of -mutated ovarian cancers has not been previously described. We aim to determine the prevalence of pathogenic or likely pathogenic mutations in ovarian cancer and describe a case of -mutated metastatic ovarian cancer with a durable response to osimertinib, an EGFR-directed targeted therapy.

View Article and Find Full Text PDF

Reply to: Comments on the Study of Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With -Mutant Lung Cancer.

JCO Precis Oncol

September 2025

Monica F. Chen, MD, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, Daniel Gomez, MD, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, and Helena A. Yu, MD, Division of Solid Tumor Oncology, Depart

View Article and Find Full Text PDF

Objectives: The 9th edition of the Tumor, Node, Metastasis (TNM-9) lung cancer classification is set to replace the 8th edition (TNM-8) starting in 2025. Key updates include the splitting of the mediastinal nodal category N2 into single- and multiple-station involvement, as well as the classification of multiple extrathoracic metastatic lesions as involving a single organ system (M1c1) or multiple organ systems (M1c2). This study aimed to assess how the TNM-9 revisions affect the final staging of lung cancer patients and how these changes correlate with overall survival (OS).

View Article and Find Full Text PDF